SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback